Lipid Infusion in Dialysis Patients With Endotoxemia

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
FatigueEnd Stage Renal Disease (ESRD)
Interventions
DRUG

Lipidose

Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.

DRUG

Placebo

Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.

Trial Locations (1)

10021

Rogosin Manhattan Dialysis Center, New York

All Listed Sponsors
collaborator

The Rogosin Institute

OTHER

lead

Sepsicure

INDUSTRY

NCT00506454 - Lipid Infusion in Dialysis Patients With Endotoxemia | Biotech Hunter | Biotech Hunter